ArticleMicrosystems & nanoengineering2022
Modular micro-PCR system for the onsite rapid diagnosis of COVID-19.
Article in Microsystems & nanoengineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Malaria serology for surveillance, insights into immunity, and vaccine development.Infection and immunity · 2026Review
- A Portable Dual-Mode Microfluidic Device Integrating RT-qPCR and RT-LAMP for Rapid Nucleic Acid Detection in Point-of-Care Testing.Biosensors · 2026Article
- Advancing Point-of-Care Healthcare Diagnostics to Tackle Future Outbreaks and Pandemics: Nanotechnology-Driven Developments and Impact on Rapid Pathogen Detection.Environment & health (Washington, D.C.) · 2025Article
- Towards practical point-of-care quick, ubiquitous, integrated, cost-efficient molecular diagnostic Kit (QUICK) PCR for future pandemic response.Microsystems & nanoengineering · 2025Review
- Laboratory Validation of a Fully Automated Point-of-Care Device for High-Order Multiplexing Real-Time PCR Detection of Respiratory Pathogens.Diagnostics (Basel, Switzerland) · 2025Article
- Infectious disease diagnostic device using rapid and efficient qPCR assays on a multi-target chip: idream-qPCR.Microsystems & nanoengineering · 2025Article
- Compact multiplex PCR device for HIV-1 and HIV-2 viral load determination from finger-prick whole blood in resource-limited settings.Biosensors & bioelectronics · 2025Article
- Quantitative and dynamic profiling of human gut core microbiota by real-time PCR.Applied microbiology and biotechnology · 2024Article
- Recent Advances in Development of Biosensors for Monitoring of Airborne Microorganisms.Iranian journal of biotechnology · 2024Review
- Rapid Nucleic Acid Diagnostic Technology for Pandemic Diseases.Molecules (Basel, Switzerland) · 2024Review
- Article
- Biporous silica nanostructure-induced nanovortex in microfluidics for nucleic acid enrichment, isolation, and PCR-free detection.Nature communications · 2024Article
- Integrated point-of-care RT-PCR methods during and after COVID-19 pandemic.Virusdisease · 2023Review
- Multiplexed CRISPR-based Methods for Pathogen Nucleic Acid Detection.Current opinion in biomedical engineering · 2023Article
- Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions.Biomedical microdevices · 2023Review
- Modular microfluidics for life sciences.Journal of nanobiotechnology · 2023Review
- An Aluminum-Based Microfluidic Chip for Polymerase Chain Reaction Diagnosis.Molecules (Basel, Switzerland) · 2023Article
- C-MEMS-derived glassy carbon electrochemical biosensors for rapid detection of SARS-CoV-2 spike protein.Microsystems & nanoengineering · 2023Article
- Smart Nanostructured Materials for SARS-CoV-2 and Variants Prevention, Biosensing and Vaccination.Biosensors · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective containment of the COVID-19 pandemic requires rapid and accurate detection of the pathogen. Polymerase chain reaction (PCR) remains the gold standard for COVID-19 confirmation. In this article, we report the performance of a cost-effective modular microfluidic reverse transcription (RT)-PCR and RT-loop mediated isothermal amplification (RT-LAMP) platform, Epidax®, for the point-of-care testing and confirmation of SARS-CoV-2. This platform is versatile and can be reconfigured either for screening using endpoint RT-PCR or RT-LAMP tests or for confirmatory tests using real-time RT-PCR. Epidax® is highly sensitive and detects as little as 1 RNA copy per µL for real-time and endpoint RT-PCR, while using only half of the reagents. We achieved comparable results with those of a commercial platform when detecting SARS-CoV-2 viruses from 81 clinical RNA extracts. Epidax® can also detect SARS-CoV-2 from 44 nasopharyngeal samples without RNA extraction by using a direct RT-PCR assay, which shortens the sample-to-answer time to an hour with minimal user steps. Furthermore, we validated the technology using an RT-LAMP assay on 54 clinical RNA extracts. Overall, our platform provides a sensitive, cost-effective, and accurate diagnostic solution for low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.